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Abstract 
THE EFFECTS OF FLAVOKAVAIN B AND CURCUMIN ON THE ONCOLYTIC 
ACTIVITY OF VESICULAR STOMATITIS VIRUS 
Dylan John Fehl  
B.S., Appalachian State University 
M.S. Appalachian State University 
 
Chairperson: Dr. Maryam Ahmed 
 A promising cancer treatment modality is the use of oncolytic viruses to kill cancer 
cells. One virus that is currently being studied as an oncolytic agent is vesicular stomatitis 
virus (VSV). We are interested in developing the rM51R-M virus, a matrix (M) protein 
mutant of VSV, as a candidate oncolytic agent due to its capacity to effectively kill cancer 
cells and its low virulence in vivo; however, prostate cancer cell lines like PC-3 are relatively 
resistant to infection with rM51R-M virus. Studies have shown that the transcription factor 
NF-κB is constitutively active in PC-3, suggesting a role for NF-κB in induction of the 
antiviral immune response and invasiveness in PC-3 cells. We hypothesize that the inhibition 
of NF-κB in cancer cells will render them susceptible to oncolytic VSV. Our goal is to 
determine the ability of natural compounds known to inhibit NF-κB (flavokavain B and 
curcumin) to suppress the antiviral immune response that may promote VSV induced cell 
killing of cancer cells. Our results show that pretreatment of PC3 cells with flavokavain and 
curcumin inhibited the phosphorylation and activation of STAT1, a key player in the antiviral 
immune response.  Furthermore, curcumin potentiated VSV-induced oncolysis after 24 hours 
post-infection; however, flavokavain B did not augment PC-3 cell death by VSV. Neither 
 
v 
curcumin nor flavokavain B decreased viral protein expression in vitro, as measured by 35S-
Methionine metabolic labeling. Additionally, pretreatment of cells with curcumin prior to 
infection led to a cumulative decrease in expression of the proapoptotic protein, BCL-XL as 
determined by Western blot analysis. These results suggest that natural products have the 
potential to synergize with oncolytic VSV therapies. Ongoing studies will determine the 
mechanisms by which these products promote anti-cancer effects and aid in oncolytic 
therapies.
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INTRODUCTION 
 Current treatment options for a variety of different types of cancers are relegated to 
surgical intervention, radiation administration, and chemotherapeutics; however, patients 
undergoing these therapies suffer from poor survival rates in the case of many cancers due to 
multiple factors, including the development of resistance to drugs and the presence of 
undetectable micrometastases. Researchers have sought alternative treatments to these varied 
cancers. Alternative options currently available to patients include immunotherapies as well 
as the delivery of anti-cancer genes to the tumor site using different gene therapy protocols, 
including bacterial and viral delivery systems (19). In the last 20 years, there has been great 
interest in developing oncolytic viral agents such as modified recombinant adenovirus, for 
the treatment of cancer (17, 19, 33) due to the natural ability of viruses to replicate in tumors, 
spread to distal metastatic sites, and kill tumor cells.  
Oncolytic viruses are viruses that kill cancer cells, either directly by inducing 
apoptosis or indirectly by eliciting an immune response (10, 19, 36, 37). Generally, viruses 
that are considered attractive oncolytic agents have to be able to effectively replicate in 
cancer cells, to have the ability to spread to surrounding susceptible tissues like metastases, 
and to preferentially kill cancer cells while leaving normal, healthy cells intact. Some of the 
first lab adapted oncolytic viruses to be studied were the recombinant adenoviruses. The 
major drawback of using adenovirus and other human viruses as tools for killing cancer cells 
is the heavy genetic recombination required to render them non-pathogenic (33). 
Additionally, these vectors require local administration, as intravenous administration has 
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shown to be less efficacious due to the liver tropism of these adenoviral vectors which results 
in sequestration (33). Alternative viruses which are not normally pathogenic to humans and 
are not hepatotropic, such as vesicular stomatitis virus (VSV), are currently being 
investigated for their ability to preferentially infect and kill cancer cells (2, 32, 33).  
VSV is a negative-stranded neurotropic RNA virus that is a member of the family 
Rhabdoviridae, which includes the human rabies virus; however, unlike rabies virus, VSV is 
a pathogen of livestock, such as cattle, pigs and horses. Although VSV rarely infects humans, 
infection of humans with field strains of VSV is occasionally associated with acute febrile 
illness. Recent studies have demonstrated that less pathogenic, lab-adapted strains of VSV 
preferentially kill cancer cells in vitro and in vivo (2, 4). This is due to the fact that many 
cancer cells have defects in their antiviral response, such as the type I interferon (IFN) 
response, thus rendering them susceptible to the oncolytic effects of VSV (2, 4, 36, 37). In 
addition to this feature, there are several advantages of using VSV as an oncolytic agent. 
Because VSV is a pathogen of livestock, there is a low probability of acquiring immunity to 
this vector in the general human population. With the advent of reverse genetics techniques, 
the virus genome may be altered readily; and foreign genes, such as immunomodulatory 
genes, may be incorporated into the genome of VSV. Furthermore, little recombinant 
modification is required to render this virus avirulent in vivo (2). Currently, in our lab, two 
strains of VSV are being tested in preclinical trials as potential oncolytic vectors, rwt and r-
M51R-M viruses. These strains are isogeneic to one another with the exception of the matrix 
(M) protein. The M protein of VSV has two main functions in infected cells. It is critical for 
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virus assembly and is responsible for the inhibition of host gene expression. The rwt virus is 
a recombinant wild type (wt) virus derived from several wt strains of VSV. The wt M protein 
in rwt virus potently shuts off host gene expression including expression of genes in the 
antiviral immune response. r-M51R-M virus expresses a mutant M protein containing a 
methionine (M) to arginine (R) substitution at position 51 of the amino acid sequence 
(M51R). This M51R M protein mutation renders this virus defective at inhibiting host gene 
expression, including expression of genes in the antiviral response (3); therefore, rM51R-M 
virus has been shown to be a more selective anti-cancer agent due to its ability to effectively 
kill cancer cells, while sparing normal cells due to enhancement of antiviral responses in 
these cells. A major drawback with VSV and other viral vectors is that not all cancer cells are 
susceptible to infection and killing by oncolytic viruses (2, 4). This is due to the fact that 
some cancer cells acquire mutations that allow them to maintain antiviral responses and/or 
develop resistance to apoptotic signals; therefore, in order to effectively treat cancer cells, it 
is important to understand and target these specific pathways.  
My project involves the investigation of oncolytic VSV therapies for prostate cancers. 
Prostate cancer is a leading cause of cancer-related morbidity and mortality in men in the 
Western world (5, 29). Most prostate cancer-related deaths are due to advanced disease 
resulting from any combination of lymphatic, blood, or contiguous local spread. Management 
of the metastatic disease involves combination therapeutic regiments including cytotoxic, 
hormonal, and immunotherapeutic treatments (39). Although the expanding array of 
treatment options offer promise, many are constrained in terms of tolerance, efficacy, and 
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cross-resistance. Therefore, second-line treatment options are limited and many patients with 
metastatic prostate cancer die within five years of diagnosis. Because of this, there is great 
need for the development of non-conventional therapeutic approaches. 
 
Previous studies by Ahmed, Cramer, and Lyles (2004) have demonstrated that 
prostate carcinoma cell lines exhibit different sensitivities to VSV infection. PC-3 prostate 
cancer cells were shown to be highly resistant to infection whereas LNCaP cells were shown 
to be permissive to VSV infection and subsequent oncolytic activity (2). This differential 
sensitivity to the virus may be due to the constitutive activation of antiviral genes detected in 
the PC-3 cells as compared to LNCaP cells (2, 6). Furthermore, studies have indicated that 
proliferative signaling pathways are enhanced in PC3 cells as compared to LNCaP cells. We 
hypothesize that the attenuation of antiviral and proliferative cell signaling pathways may 
sensitize resistant cells to oncolytic viral activity. The goal of my project is to promote the 
oncolytic ability of VSV by suppressing antiviral, anti-apoptotic, or proliferative pathways in 
prostate cancer cells using natural products that are known to inhibit these pathways. During 
oncogenesis multiple pathways involved in proliferation, apoptotic responses, cytokine 
secretion, and cell adhesion can become disregulated resulting in overproliferation and 
resistance to apoptotic signals. Of these signaling pathways, two relatively important signal 
cascades have been implicated in tumorigenesis and tumor progression, NF-κB and Akt (11, 
12, 14, 24, 34, 35, 42).  
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NF-κB (nuclear factor kappa B) is a transcription factor that has various functions in 
cells, including the control of cancer development, inflammation, apoptosis, and antiviral 
responses (11, 14). Studies have shown that NF-κB is upregulated or constitutively active in 
many cancer cell lines, including PC-3 cells.  A consequence of this upregulated or 
constitutive activity is that cancer cells develop resistance to being killed by common 
therapeutic agents due, in part, to upregulation of anti-apoptotic factors. Furthermore, NF-κB 
activity may enhance antiviral responses due to the increased expression of genes whose 
products regulate antiviral activity, including cytokines such as type I IFN (2, 4, 6, 14). This 
has generated interest in the effects of downregulating cytokines and modulating intracellular 
signals in the NF-κB pathway in certain cancers to make them more susceptible to 
chemotherapy (9, 13, 20, 24, 32, 42, 43). 
Akt is a proliferative signal associated with mitogen activated protein kinases 
(MAPK) signaling pathways, which activate the CREB transcription factor by 
phosphorylation. This activation leads to increased proliferative signals within the cell in 
addition to upregulation of growth factor receptors (35). An overactivation of the Akt 
signaling pathway in cancer cells is thus associated with uncontrolled growth and 
tumorigenesis in some instances; therefore, the Akt signaling pathway has also become an 
attractive target for both chemotherapeutics and adjunctive therapies. 
The PC-3 prostate carcinoma cell line has been shown to have constitutive activation 
of NF-κB in addition to upregulated Akt phosphorylation (3, 14, 18, 34). Constitutive or 
6 
 
 
overactivation of these pathways leads to an increase in proliferative signaling, upregulation 
of anti-apoptotic factors, and a decrease in pro-apoptotic factors. This disregulation results in 
an increase in cell division and a decrease in sensitivity to apoptosis-inducing agents, 
including various chemotherapeutic drugs.  NF-κB has previously been shown to regulate the 
expression of apoptotic factors such as Bax, a pro-apoptotic factor, and the anti-apoptotic 
factors BCL-2 and BCL-XL (11, 32). The ratio of these factors determines the apoptotic fate 
of the cells (8, 31). By attenuating these pathways in these cancer cells, it may be possible to 
sensitize them to apoptotic responses and decrease proliferative signaling.  
 Recent interest in targeting NF-κB and Akt in conventional chemotherapeutics has 
yielded lists of bioactive pharmaceutical compounds and naturally derived plant compounds 
shown to impact cancer cell lines (9, 13, 20, 24, 42, 43). Of these, curcumin and flavokavain 
B are of particular interest given their ability to block the activity of NF-κB and Akt. 
Curcumin is a phenolic coloring agent found in turmeric that has been shown to exhibit 
strong anti-inflammatory and anti-cancer properties (9). Flavokavain B is a chalcone derived 
from the root of kava kava, a common natural remedy for anxiety that also attenuates 
inflammatory and proliferative signal cascades like NF-κB (42).  
NF-κB regulates the innate antiviral response by controlling the transcription of the 
antiviral cytokines, type 1 IFN (38). NF-κB associates with an inhibitory factor, IκB, in the 
cytoplasm preventing NF-κB’s translocation to the nucleus and subsequent transcriptional 
activity; however, upon phosphorylation of IkBα by IKK, NF-κB is released and is able to 
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translocate to the nucleus to promote transcription of a variety of genes. Studies have 
indicated that curcumin and flavokavain B regulate NF-κB by inhibiting the phosphorylation 
of IκBα by IKK, thereby inhibiting the translocation of NF-κB to the nucleus (9, 42). This 
block prevents the transcriptional activity of this protein resulting in the reduction of anti-
apoptotic factors and inflammatory cytokines produced within these cells (9, 13, 20, 24, 32, 
42, 43). What is not known is whether these compounds affect the antiviral responses in 
cancer cells. Studies have shown that resveratrol, another natural modulator of NF-κB 
activity, increases the replication of hepatitis C virus in cells in culture due to suppression of 
the host antiviral response (27), thus demonstrating a link between NF-κB inhibition and 
increased permissivity of cells to virus infection. Blocking the antiviral response in cancer 
cells by commonly known bioactive compounds may sensitize them to replication and killing 
by oncolytic viruses. In addition, by inhibiting NF-κB activity in cancer cells, one may also 
have the potential to decrease the ability of cells to proliferate and survive. Due to the low 
success rate of current treatments, it is important to test alternative agents and synergistic 
combination therapies in order to treat cancers that are resistant to common therapeutics. 
Curcumin and flavokavain B have also been implicated in attenuating the Akt 
signaling pathway (13, 24). Flavokavain B has previously been shown to downregulate Akt 
phosphorylation sensitizing HSC-3 cells to G2/M cell cycle arrest and apoptosis via the 
differential expression of BCL-2/Bax (16). Curcumin inhibits Akt through the 
dephosphylation of downstream factors in the Akt pathway by the PTEN phosphatase (13, 
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24). Downregulating overactivation of proliferative signaling pathways like Akt and others 
are also promising targets for both conventional and adjunctive cancer therapies.  
The purpose of this project is to determine if downregulating signaling pathways 
controlling apoptosis and antiviral responses in VSV-resistant cancer cells (PC-3) will render 
these cells more susceptible to infection. Naturally derived plant compounds flavokavain B 
and curcumin have previously been shown to decrease NF-κB and Akt activation, resulting in 
a decrease in anti-apoptotic factors and an increase in cell death in several cancer systems (9, 
16, 24, 30, 42); however, data on combination therapies is sparse. Previous studies have 
shown that curcumin potentiates the action of the oncolytic action of the bacterium Bacillus 
calmette-guerin by upregulating apoptotic factors and downregulating NF-κB, demonstrating 
that combination therapies may be efficacious (17). The link between downregulating NF-κB 
and VSV mediated oncolysis has yet to be established. 
We hypothesize that downregulating NF-κB and Akt activation by using curcumin 
and flavokavain B in PC-3 cells will render them more susceptible to VSV oncolytic activity 
and increase apoptotic signaling in these cells. This project will determine the ability of 
flavokavain B and curcumin to down-regulate the antiviral immune response in prostate 
cancer cells with constitutive NF-κB activity. In addition, we will determine if these 
compounds synergize with VSV to promote killing of prostate cancer cells that are normally 
resistant to VSV. Lastly, we will elucidate if these compounds enhance virus replication in 
the VSV-resistant prostate cancer cell line, PC-3. Upon completion of these studies, we hope 
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to be in a position to evaluate the utility of using such compounds to promote VSV oncolytic 
therapies.  
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MATERIALS AND METHODS 
Cell Lines and Virus: 
 PC-3 prostate carcinoma cells were propagated in RPMI media supplemented with 
10% fetal bovine serum (FBS) in 100mm tissue culture plates and incubated at 37°C + 5% 
CO2. Recombinant wild-type virus and the matrix protein mutant (rM51R-M) virus were a 
generous gift from Dr. Doulas Lyles from Wake Forest University Baptist Medical Center 
(Winston-Salem, NC). Viral titers for the rwt-VSV, rwt-VSV-GFP, rM51R-VSV, and 
rM51R-VSV-GFP were determined by the standard VSV plaque assay analysis. Specifically, 
rwt-VSV and rM51R-VSV stock samples were grown in BHK cells at 75-85% confluency in 
DMEM plus 10% FBS. 24h post-infection the media containing progeny virus was collected 
and centrifuged at 1200 rpm for five minutes to remove cellular debris. Virus supernatant 
was aliquoted and stored at -80°C. For the plaque assay, two 6-well dishes were seeded with 
BHK cells and allowed to grow to 75-85% confluence. The virus stocks were subjected to 10 
step serial dilutions and added to the cells in 60 well dishes in duplicate. After allowing 
viruses to attach to cells for 1h, cells were overlayed with oxoid agar containing DMEM plus 
2% FBS. Cells were incubated at 37°C for 24-48h until plaques were visible, at which time 
cells were stained with Crystal Violet to visualize the plaques. Viral titer was calculated by 
counting the number of plaques at each dilution and multiplying this number by the dilution 
factor. 
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MTT Cell Viability Assay: 
 Viability of VSV-infected and flavokavain B or curcumin-treated cells was measured 
by MTT assay (as described in 26). PC-3 cells grown in 96-well plates were treated with 
25µmol, 60µmol, and 100µmol curcumin or 1µg/mL, 5µg/mL, and 25µg/mL flavokavain B 
and infected with rwt-VSV and rM51R-VSV at MOIs of 10 and 50 pfu/ml. At 24h, 48h, and 
72h post-infection the cells were incubated with the MTT solution provided by Roche 
Applied Science (Penzberg, Germany) for 4h and incubated overnight at 37°C and 5% CO2 
in solubilization solution. The optical density (OD) at 550nm was then determined by a 96-
well spectrophotometer plate reader. The reference wavelength was set to 650 nm. The OD is 
an arbitrary measure of the number of metabolically active cells in culture. All data was 
normalized as a ratio to mock-infected cells. Experiments were run in triplicate and were 
carried out 3-5 times. Error was determined by standard deviation from the mean. 
Western Blot analysis: 
Relative intracellular concentrations of Bax, BCL-2, and BCL-XL were determined 
by Western blot analysis. Β-actin was used as an internal loading control. PC-3 cells grown 
in 6-well plates were treated with 25µmol and 60µmol curcumin or 1µg/mL and 5µg/mL 
flavokavain B 6h prior to infection with rwt-VSV or rM51R-VSV at an MOI of 10. As 
controls, cells were mock infected, infected with virus alone, or treated with the natural 
compounds alone. At 18h post infection, the media was removed and cells were washed 
twice with 1X phosphate buffered saline (PBS). Cells were directly lysed in RIPA buffer 
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containing aprotinin and stored at -80°C until use. A BCA assay was conducted using the 
manufacturer’s (Thermo Scientific) recommended protocol to determine the total protein 
concentration in the cell lysates. 30µg total protein for each lysate was subjected to SDS-
polyacrylamide gel electrophoresis using 10% polyacrylamide gels. The proteins were 
transferred onto a nitrocellulose membrane. The membrane was then blocked using 5% dry 
milk and 0.1% tris-buffered saline-tween 20 (TBS-T) pH 7.6 20 mM Tris at room 
temperature (RT) for one hour and incubated with the primary antibody of interest (Cell 
Signaling Technology) overnight at 4°C in 5%BSA+0.1% TBS-T. The blot was then 
incubated with goat-anti-rabbit horseradish peroxidase (HRP) linked secondary antibody. 
Pico or Dura (Thermo Scientific) luminol and stable peroxide substrate were used to 
visualize the signal on Gememate Blue Lite Autorad film. Imagequant TL v 2005 software 
was used to quantitate relative band intensities. Experiments were carried out three times. 
Data was normalized to a ratio of β-actin expression in each lane.  
35S Metabolic Labeling Assay:   
 The rates of host and viral protein synthesis were determined by 35S metabolic 
labeling assay. PC-3 cells grown in 6-well plates were treated with 25µmol and 60µmol 
curcumin or 1µg/mL and 5µg/mL flavokavain B 6h prior to infection with rwt-VSV or 
rM51R-VSV at an MOI of 10. Mock-infected and virus infected cells served as controls The 
media was removed at 24h post-infection and methionine-deficient RPMI media 
supplemented with L-glutamine and 2% FBS was added to the wells for methionine 
13 
 
 
starvation for 20 minutes. The medium was then removed, and the cells were pulse labeled 
with 200µL of methionine deficient RPMI media supplemented with 2% FBS and 20µCi of 
35S-Methionine. The media were removed after 15 minutes, and the cells were washed twice 
with PBS and lysed in 150µL RIPA buffer containing the protease inhibitor, aprotinin. 
Protein concentrations were determined by BCA assay (Thermo Scientific). A standard curve 
was generated using a serial dilution of BSA, which was used to determine the protein 
concentration of the cell lysates. Twenty micrograms (µg) of total protein for each lysate was 
then subjected to SDS-PAGE using a 12% polyacrylamide gel. The gels were stained using 
the Coomassie Blue staining method. Specifically, gels were fixed in a 50% methanol, 10% 
acetic acid solution for 1h and stained in a 0.25% Coomassie Brilliant Blue R-250, 50% 
methanol, and 10% acetic acid solution for 45 min with gentle agitation. The gels were later 
destained for 2h using a 40% methanol and 10% acetic acid solution and dried at 80°C for 2h 
under 26”Hg vacuum using a Bio-Rad model 583 gel dryer and Bio-Rad HydroTech vacuum 
pump. After drying, the gels were exposed to phosphor screen overnight and imaged using a 
Typhoon variable mode scanner. Host and viral protein bands were quantified using 
ImageQuant 5.1 software. Host protein bands were detected in the regions of the gels that 
were devoid of viral proteins, and band intensities were normalized as a ratio to mock. Viral 
M and N protein band intensities were normalized as a ratio to M and N protein band 
intensities in cells infected with rwt virus for 8h. Experiments were carried out three times. 
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Flow Cytometry Analysis: 
 PC-3 cells were grown in 6 and 12 well dishes and treated with 5µg/mL flavokavain 
B and 60µmol curcumin 6h prior to infection with GFP expressing rwt and M51R viruses at 
an MOI of 10. At 6, 12, 18, 24, and 48h postinfection, the cells were washed with sterile 
PBS, trypsinized, and resuspended in 400µL ice-cold PBS. Cells were then treated with 5µL 
7-AAD for 20 minutes in the dark prior to flow cytometry analysis. A Beckman-Coulter 
Cytometrics FC 500 MPL was used to determine GFP expression and 7-AAD fluorescence. 
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RESULTS 
Six hour pretreatment with Curcumin, but not Flavokavain B, augments the ability of 
VSV to kill PC-3 after 24 hours.  
 Previous data in our laboratory indicate that flavokavain B and curcumin reduce the 
activation of STAT1, an upstream transcription factor in the type I IFN response, in PC-3 
cells upon infection with VSV (data not shown).  These results suggest that these natural 
products may reduce the constitutive activation of the type 1 IFN response in PC-3 cells and 
render these cells more susceptible to infection and killing by VSV.  To assess the ability of 
VSV to kill PC-3 cells upon treatment with curcumin, cell viability was determined by MTT 
cell viability assays. These assays determine the metabolic activity of cells by the action of 
mitochondrial reductase in live cells reducing the yellow MTT tetrazolium salt into a purple 
fomazan product, the OD of which can be read to derive a relative measure of live cells in 
culture. For data shown in Figures 1A and 1B, cells were pretreated with curcumin (25, 60 
and 100µmol) for 6h, followed by infection with wt or M protein mutant VSV at MOI of 
10pfu/cell.  At 24h (Fig. 1A) and 48h (Fig. 1B) post infection, cell viability was determined, 
and data were expressed as a percentage of mock cells (cells that were not subjected to 
treatment with drugs and infection with viruses). Data in Figure 1 revealed that curcumin or 
virus-infection alone was ineffective at killing PC3 cells by 24h (Fig. 1A; untreated cells); 
however, 6h pretreatment of PC-3 cells with 25µmol and 60µmol curcumin significantly 
promoted the ability of VSV to kill PC-3 cells as indicated by a reduction in cell viability to 
40% to 60% of mock cells by 24h (Fig. 1A). This result was apparent upon infection of cells 
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with both strains of virus and was statistically different from results seen in cells treated with 
curcumin or infected with virus alone (p<0.05, Fig. 1A). By 48h postinfection this effect was 
not statistically significant, yet there was an increasing trend in VSV induced cell killing 
(p=0.09, Fig. 1B).  In contrast, co-treatment of cells with curcumin and virus  did not lead to 
a decrease in cell viability as compared to cells singly treated with curcumin or infected with 
virus at 24h (Fig. 1C) or 48h (Fig. 1D). These data indicate that pretreatment with curcumin 
may sensitize PC-3 cells to VSV mediated oncolytic activity. 
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Figure 1: Pretreatment of PC3 cells with curcumin augments the oncolytic activity of VSV 
when infected at an MOI of 10pfu/cell. PC3 cells were pretreated with curcumin at 
concentrations of 25, 60, or 100µmol for 6h prior to infection with rwt and r-M51R-M 
viruses (A, B) or co-treated with curcumin and viruses (C, D).  Cells were infected for 24h 
(A, C) or 48h (B, D) and subjected to MTT assay to determine cell viability. Data was 
normalized as a percentage of mock cells (untreated and uninfected) and is shown as the 
averages + standard error for 3-5 experiments. Statistical analysis was carried out using 
unpaired Student’s t-test.  
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Previous studies have shown that PC-3 cells are not synchronously infected by VSV 
at an MOI of 10, but rather at an MOI of 50 (6). Data in Figure 1 indicates that pretreatment 
with 25 and 60µmol curcumin augments VSV mediated oncolysis at an MOI of 10pfu/mL, 
suggesting a potential synergistic effect between pretreatment with curcumin and the virus. 
Synchronous infection of PC-3 cells by VSV may further augment oncolytic activity. MTT 
cell viability assays were used to determine if there was an increase in VSV mediated 
oncolysis in PC-3 cells treated with 25, 60, and 100µmol curcumin and synchronously 
infected for 24h and 48h. For data shown in Figure 2A and 2B, PC-3 cells were pretreated for 
6h with 25, 60 and 100µmol curcumin and infected with the wt and M protein mutant virus at 
an MOI of 50pfu/mL. At 24h (Fig. 2A), infection with wt virus alone reduced cell viability 
by approximately 40% while the M protein mutant reduced cell viability by 10%; however, 
pretreatment with curcumin alone did not reduce cell viability in uninfected cells at 24h (Fig. 
2A).  Treatment with curcumin and infection by both strains of virus did not significantly 
reduce cell viability compared to drug alone; however, there was a trend in an increase in cell 
death with curcumin treatment compared to virus alone (Figure 2A). By 48h postinfection, 
this trend was not as apparent (Fig. 2B). Similarly to results shown in Figure 1, co-treatment 
with curcumin and infection by the virus did not reduce cell viability compared to virus alone 
(Fig. 2C and 2D). There was a slight increase in death in cells treated with 60 and 100µmol 
curcumin and infected with the M protein mutant virus compared to rM51R-M infection 
alone; however, these trends were not statistically significant (Fig. 2C). By 48h postinfection, 
cells pretreated with curcumin did not show any increase in cell death compared to virus 
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alone; although, there was a trend towards a reduction in cell viability in cells treated alone 
that was concentration dependent (Fig. 2D). These data suggest that treatment with curcumin 
can reduce PC-3 cell viability when synchronously infected with VSV, but these reductions 
are not significant compared to virus infection alone. 
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Figure 2: Pretreatment of PC3 cells with curcumin does not augment the oncolytic activity of 
VSV when infected synchronously at an MOI of 50pfu/cell. PC3 cells were pretreated with 
curcumin at concentrations of 25, 60, or 100µmol for 6h prior to infection with rwt and r-
M51R-M viruses (A, B) or co-treated with curcumin and viruses (C, D).  Cells were infected 
for 24h (A, C) or 48h (B, D) and subjected to MTT assay to determine cell viability. Data 
was normalized as a percentage of mock cells (untreated and uninfected) and is shown as the 
averages + standard error for 3-5 experiments. Statistical analysis was carried out using 
unpaired Student’s t-test.  
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 In addition to curcumin, other phytochemicals have been shown to differentially 
regulate cell proliferation and survival pathways. One of these phytochemicals, flavokavain 
B, also downregulates the NF-κB pathway by reducing IKK activity thereby sensitizing cells 
to apoptotic stressors (43). Treatment with flavokavain B could potentially render PC-3 cells 
susceptible to VSV infection by attenuating the antiviral and proliferative response pathways 
regulated by NF-κB. To determine whether flavokavain B also augments VSV’s oncolytic 
capacity, PC-3 cells were treated in a manner similar to the curcumin treatments previously 
outlined and subjected to MTT cell viability assays. Cells were pretreated for 6h or co-treated 
with 1µg/mL, 5µg/mL, or 25µg/mL flavokavain B and infected with the wt and M protein 
mutant strains of VSV or mock treated. Cell viability was then assessed 24h and 48h 
postinfection by MTT analysis. Data was normalized to mock infected cells and subjected to 
an unpaired Student’s t-test, comparing treated and infected cells to viral infection alone. 
Data shown in Figure 3 represents PC-3 cells infected by both strains of virus at an MOI of 
10pfu/cell. Unlike the results for curcumin shown in Figure 1, a 6h pretreatment with 
flavokavain B did not significantly reduce cell viability by 24h or 48h postinfection 
compared to virus alone (Fig. 3A and 3B, respectively). Pretreatment with 25µg/mL 
flavokavian B alone did reduce cell viability 30% by 48h as compared to mock cells, but this 
trend was not significant (p=0.1, Fig. 3B). Similarly, cotreatment with flavokavain B and 
infection by the virus did not reduce cell viability 24h or 48h postinfection compared to virus 
alone (Fig. 3C and D, respectively). Treatment with flavokavain B alone did not reduce cell 
viability compared to mock infected cells (Fig. 3A-3D, black bars). The synergistic effect 
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between increased cell killing and sub-synchronous infection by VSV observed with 
curcumin pretreatment was not evident with flavokavain B treatment. 
 
Figure 3: Cotreament or pretreatment with flavokavain B does not potentiate the oncolytic 
activity VSV at an MOI of 10pfu/mL. (A) PC-3 cells pretreated 6h with 1µg/mL, 5µg/mL, 
and 25µg/mL flavokavain B prior to infection. Data indicates 24h postinfection. (B) PC-3 
cells 48h postinfection with a 6h pretreatment of flavokavain B at the indicated 
concentrations. (C) PC-3 cells 24h postinfection cotreated with flavokavain B at the indicated 
concentrations. (D) Cell viability of PC-3 cells cotreated with flavokavain B at the indicated. 
Data indicates 48h postinfection. Data indicates average cell viability as a percentage of 
mock + standard error for 3 experiments.   
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To determine whether flavokavain B augments VSV induced cell killing upon 
synchronous infection, cells were infected with wt and M protein mutant VSV at an MOI of 
50pfu/cell and treated with flavokavain B in the manner previously described. These cells 
were then subjected to MTT cell viability assays 24h and 48h post-infection. Data shown in 
Figure 4 represents cell viability as a ratio to mock versus treatment. As shown in Figure 4A, 
a 6h pretreatment at the indicated concentrations of flavokavain B does not augment cell 
killing compared to virus infection alone by 24h post-infection. This trend persists by 48h 
post-infection; however, there is a reduction of cell viability of 30% in cells treated with 
25µg/mL flavokavain B alone (Fig. 4B, black bars). Co-treatment with flavokavain B at each 
concentration and infection by the virus did not reduce cell viability compared to virus 
infection alone at both 24h and 48h post-infection (Fig. 4C and 4D). There was an 
approximately 50% reduction in cell viability with cells treated with 25µg/mL alone. These 
data suggest that flavokavain B does not enhance VSV’s ability to kill PC-3 cells even under 
conditions of synchronous infection. Flavokavain B does exhibit some cell killing activity in 
PC3 cells in the absence of virus infection.  
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Figure 4: Cotreament or pretreatment with flavokavain B does not potentiate the oncolytic 
activity VSV when PC-3 cells are synchromously infected at an MOI of 50pfu/mL. (A) PC-3 
cells pretreated 6h with 1µg/mL, 5µg/mL, and 25µg/mL flavokavain B prior to infection. 
Data indicates 24h postinfection. (B) PC-3 cells 48h postinfection with a 6h pretreatment of 
flavokavain B at the indicated concentrations. (C) PC-3 cells 24h postinfection cotreated with 
flavokavain B at the indicated concentrations. (D) Cell viability of PC-3 cells cotreated with 
flavokavain B at the indicated. Data indicates 48h postinfection. Data indicates average cell 
viability as a percentage of mock + standard error for 3 experiments.   
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Curcumin and flavokavain B do not significantly alter expression of anti-apoptotic and 
pro-apoptotic factors in conjunction with VSV  
Previous studies have shown that VSV preferentially induces the intrinsic apoptotic 
pathway by inactivating BCL-XL and increasing Bax expression in permissive HeLa cells 
(28). The increased sensitivity of PC-3 cells pretreated with curcumin to VSV oncolytic 
activity may be due to the differential regulation of factors in the intrinsic apoptotic pathway. 
Western blot analysis was used to determine whether the reduction of cell viability correlated 
to a reduction in the expression of the anti-apoptotic factors BCL-2 and BCL-XL or an 
increase in the expression of the pro-apoptotic factor Bax. Cell viability data shown in Figure 
1 indicate that 6h pretreatment with curcumin correlated to the greatest increase in VSV 
mediated oncolysis after 24h, suggesting that the differential regulation of cell signal 
cascades promoting a synergistic effect between the drugs and the virus may take place early 
in treatment and infection. To test this, PC-3 cells were pretreated with 1 and 5µg/mL 
flavokavain B and 25 and 60µmol curcumin for 6h prior to infection by the wt and M protein 
mutant VSV at an MOI of 10pfu/cell. Cell lysates were then collected 24h post-infection and 
subjected to SDS-PAGE and immunoblot analysis for BCL-XL, BCL-2, and Bax 
concentrations. Data shown in Figure 5 are the relative band intensity normalized as a ratio to 
β-actin.  Interestingly, there was a decrease trend in BCL-XL expression in cells treated with 
curcumin and infected with VSV (Fig. 5A) even though results were not significant (p=0.08). 
This trend reflects the synergistic cell killing effect seen in Figure 1 with this treatment 
combination. Furthermore, BCL-XL expression was not consistently down-regulated in cells 
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treated with flavokavain B and infected with VSV, except when cells were treated with 
flavokavain at 25µg/ml and infected with rM51R-M virus (Fig. 5B).  BCL-2 expression was 
not altered by treatment with curcumin and flavokavain B and infection by the virus 
compared to mock (Fig. 5C and 5D). Interestingly, treatment with drug alone and infection 
by the virus alone did not reduce BCL-XL or BCL-2 expression (Fig. 5A-D). Additionally, 
Bax expression was not altered by flavokavian B, curcumin, or infection by the virus (Fig. 5E 
and 5F). These results suggest that the increase in cell killing by VSV in PC-3 cells treated 
with curcumin may be due to a decrease in expression of the antiapoptotic factor, BCL-XL; 
however, the antiapoptotic factor BCL-2 and the proapoptotic factor, Bax were minimally 
affected by this treatment combination. Furthermore, we cannot rule out the possibility that 
cells treated with curcumin and infected by the virus may not be regulated through the 
intrinsic apoptotic pathway controlled by Bax but rather another mechanism. 
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FIGURE 5: Expression of apoptotic factors in response to a 6h pretreatment of flavokavain 
or curcumin and infection of both strains of virus at an MOI of 10pfu/mL. Lysates were 
collected 24h postinfection and subjected to Western blot analysis with antibodies to BCL-
XL (A, B), BCL-2 (C, D) and Bax (E, F). Data represents average band intensity normalized 
to β-actin +standard error for 3 experiments. Top panels indicate images from bands 
subjected to development on photographic film. 
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Flavokavain B and Curcumin do not reduce viral or host protein expression   
Due to data shown in Figure 5, it is possible that the increase in cell death may not be 
due to the Bax regulated apoptotic pathway, which is the pathway wild-type VSV uses to 
induce apoptosis in permissive cells, but rather another mechanism. Previous studies have 
shown that naturally derived plant compounds have the potential to augment viral gene and 
protein expression (27). We hypothesized that treatment with curcumin or flavokavain B may 
enhance viral replication and increase potential cytopathic effects exerted by the virus. One 
indication of virus replication is the expression of viral proteins in infected cells. To 
determine if these compounds augmented or reduced viral protein replication, 35S metabolic 
labeling was used to assay the relative rates of viral and host protein expression in infected 
cells. Data in Figure 6 show results in cells treated with curcumin and infected VSV. PC-3 
cells were co-treated (Fig. 6 A,C) with 25 and 60µmol curcumin, or pretreated 6h prior to 
infection (Fig. 6B,D) by wt and rM51M mutant VSV at an MOI of 10, or mock treated. At 
24h postinfection, cells were starved of methionine using methionine deficient media and 
pulse-labeled with 35S-methionine for 15min. Cells were lysed, subjected to SDS-PAGE, and 
phosphorimaged. Representative images of SDS-PAGE gels are shown in the top of Figure 6. 
Bands corresponding to viral proteins are shown on the left. Viral M protein synthesis in each 
lane was quantified as a ratio of the M protein expression in cells infected with rwt VSV for 
6 h.  Host protein synthesis was determined by measuring the rates of host proteins in bands 
devoid of viral proteins and is expressed as a ratio of host protein expression in mock-
infected cells. As shown in Figure 6A, rates of viral protein expression were greater in cells 
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infected with rwt virus as compared to rM51R-M virus at 6h post-infection. By 12h post-
infection, the expression of viral proteins in PC3 cells infected with each virus was similar.  
Pretreatment of cells with curcumin did not significantly alter viral protein expression upon 
infection with rwt or rM51R-M virus, indicating that curcumin does not affect virus 
replication in PC-3 cells. Host protein synthesis in cells infected with rwt virus decreased to 
50% of mock by 12 h post-infection (Fig. 6B). In contrast, host protein synthesis was not 
inhibited by rM51R-M virus by 12 h postinfection due to enhancement of antiviral responses 
in cells infected with this virus (2). Upon pretreatment of cells with curcumin, host protein 
synthesis did not significantly change as compared to cells infected with each virus alone. 
These data show that curcumin pretreatment does not affect rates of host protein synthesis in 
cells infected with either virus. This is in contrast to cell viability results shown in Figure 1.  
Similarly to results in Figures 6A and 6B, co-treatment with curcumin did not impact viral 
and host protein expression compared to that in cells infected with virus alone Figure 6B and 
Figure 6D, respectively.  
To determine the rates of viral and host protein synthesis in cells treated with 
flavokavain B in conjunction with VSV, experiments similar to those shown in Figure 6 were 
conducted. Cells pretreated with 25µg/mL flavokavain B and infected with the rwt virus 
showed a 0.4 fold increase in viral protein expression at 6h post-infection, but this increase 
was not significant compared to infection by the wt virus alone (Fig. 7A). A similar trend 
was seen in cells pretreated with flavokavain B and infected with rM51R-M virus for 12h. 
Viral protein expression in cells cotreated with flavokavain B and infected by both wt and the 
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M protein mutant virus decreased slightly as compared to that in cells infected with virus as 
well, but again, results were not significant (Fig. 7B). Host protein synthesis at 6h and 12h in 
treated and infected cells was not altered compared to cells infected by the virus alone in 
cells pretreated or cotreated with curcumin (Fig. 7C and D, respectively). Overall, host 
protein expression in cells infected with the M protein mutant was higher than cells infected 
with rwt, which correlates to previous studies showing that the M protein mutant is defective 
in inhibiting host protein synthesis in cells with intact antiviral responses (3). In total, these 
data indicate that treatment of PC-3 cells with curcumin and flavokavain B does not 
significantly alter viral or host protein synthesis in infected cells, implying that these 
compounds to not negatively impact viral replication in infected cells 
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Figure 6:  Host and viral protein synthesis upon treatment of cells with curcumin and 
infection with virus for 6h and 12h as determined by 35S metabolic labeling. PC-3 cells were 
treated (B,D) or pretreated 6h (A,C) with curcumin at the indicated concentrations and 
infected with both strains of virus at an MOI of 10. Viral protein expression (A, B) is shown 
as fold change over rwt M protein at 6h postinfection. Host protein expression is shown as a 
percentage of mock (C, D). Data shown is an average of three experiments + standard error. 
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Figure 7: Host and viral protein synthesis upon treatment of PC3 cells with flavokavain B 
and infection with VSV for  6h and 12h as determined by 35S metabolic labeling. PC-3 cells 
were treated (B,D) or pretreated 6h (A,C) with flavokavain B at the indicated concentrations 
and infected with both strains of virus at an MOI of 10. Viral protein expression (A, B) is 
shown as fold change over rwt M protein at 6h postinfection. Host protein expression is 
shown as a percentage of mock (C, D). Data shown is an average of three experiments + 
standard error. 
 
To further measure virus replication in infected and treated cells, the fluorescence of 
green fluorescence protein (GFP) was measured in rwt virus engineered to express GFP (rwt-
GFP). The gene for GFP was inserted into an extra transcriptional unit between the M and G 
genes of rwt virus such that GFP expression is a measure of expression of viral genes in 
infected cells.   Cells were pretreated with curcumin or flavokavain B for 6h and infected 
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with rwt-GFP at an MOI of 10pfu/cell. At 6 and 12h postinfection, cells were harvested and 
the percentage of cells expressing GFP was determined by flow cytometry. Mock infected 
cells and cells treated with 25µg/mL flavokavain B or 60µmol curcumin were negative for 
GFP expression at both 6 and 12h (Fig. 8). By 6h post-infection, there was a slight reduction 
in GFP expression in cells treated with either drug and infected with both strains of virus. 
Specifically, there was an approximately 10% reduction in the percentage of GFP-positive 
cells upon drug treatment and infection with rwt virus and a 30% reduction for the M protein 
mutant virus (data not statistically significant). By 12h postinfection, these reductions were 
no longer evident, as nearly 100% of all infected cells were positive for GFP expression. 
These data suggest that curcumin and flavokavain B may slightly reduce early viral 
replication; but by 12h, the effects of these drugs on virus replication are not apparent. These 
natural products do not inhibit viral genome replication which may benefit combination 
therapeutic approaches with oncolytic viruses like VSV by being innocuous to viral 
replication processes. 
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Figure 8: Flow cytometry analysis of PC-3 cells treated with flavokavain B (25µg/mL) or 
curcumin (60µmol) and infected with GFP expressing virus for 6 and 12 hours.  Treatment 
with either drug did not significantly reduce or enhance GFP expression in infected cells. 
Data shown is the average of three experiments + standard error. 
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DISCUSSION 
Numerous studies have shown that many cancer cells are resistant to the oncolytic 
effects of virus infections (2, 3). Studies have suggested that this may be due, in part, to the 
ability of cancer cells to retain antiviral responses and to prevent virus replication and cell 
death (6). The data presented here suggests that naturally derived plant compounds can 
augment the ability of an oncolytic viral vector to kill a prostate cancer cell line naturally 
resistant to the cytopathic effects of VSV. Furthermore, data collected in our lab indicate that 
the natural compounds, curcumin and flavokavain B, reduce the activation of an essential 
transcription factor in the antiviral response, STAT1 (data not shown). Recent studies have 
shown that equol and resveratrol effectively potentiate the action of a mutant adenoviral 
oncolytic vector, AdΔΔ, in PC-3 and DU145 cells by increasing apoptotic signals from 
PARP and caspase-3 cleavage (1). Thus, there is increasing evidence that plant compounds 
can effectively synergize with oncolytic viral vectors perhaps by increasing sensitivity of 
cells to apoptosis and by decreasing production of antiviral genes.  
Data shown here indicates that a 6h pretreatment of curcumin reduces PC-3 cell 
viability in a concentration dependent manner upon infection with both the wt and M protein 
mutant strains of VSV (Fig. 1A). The synergistic effect of curcumin and virus on killing of 
cancer cells was observed at 24h postinfection; but by 48h, results were not significant. In 
addition, co-treatment of curcumin and virus did not promote killing of PC3 cells as 
compared to virus or curcumin alone; therefore, these results indicate that pretreatment of 
cells with curcumin is required to enhance the ability of VSV to kill cancer cells. This may 
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be due to attenuation of proliferative and/or immune signaling pathways by curcumin 
allowing virus to effectively enter, replicate, and induce cytopathology in these cells.  This 
also reinforces the data by Carey et al. (6) that the early steps of the virus replication cycle 
are delayed in PC3 cells. They show that PC-3 cells constitutively express antiviral factors 
that reduce primary transcription upon infection reducing genomic expression. Additionally, 
early protein expression is reduced in PC-3 cells upon asynchronous infection with VSV. The 
reduction of viral protein and RNA expression in the early phases of infection is due to the 
over-expression and constitutive activation of antiviral effector proteins like OAS, ISG15, 
and Mx proteins (6). Carey et al. were able to demonstrate that PC-3 cells are more resistant 
to VSV infection by the activation of antiviral factors in these cells. Curcumin may be 
decreasing the expression of these factors thus rendering PC-3 cells more susceptible to VSV 
infection and subsequent oncolysis. 
My results also showed that the synergistic effect of curcumin and virus was only 
observed when cells were infected asynchronously (MOI 10pfu/cell) such that not all cells 
were initially infected. When cells were infected synchronously at a MOI of 50pfu/cell, 
curcumin was unable to augment VSV-induced cell killing. A synchronous infection of cells 
measures the cytopathic effect of virus on all cells in the environment, whereas asynchronous 
infections measure the ability of the virus to spread throughout the culture where it is 
influenced by factors in the environment. These results indicate that VSV spread was 
promoted by curcumin pre-treatment and suggest that the cytopathic effect being exerted by 
the virus may not solely be responsible for the increase in PC-3 cell death. Attenuation of the 
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immune response by curcumin may be enhancing the ability of virus to spread to surrounding 
cells and to induce their effects.  In our lab, we are currently investigating the antiviral 
response in prostate cancer cells treated with curcumin by measuring the type I IFN secreted 
in the culture supernatant.   
 It is a possibility that the attenuation of proliferative and immune processes in PC3 
cells by curcumin may be transient. Previous studies have shown that curcumin reduces NF-
κB activity and several other proliferative signal pathways in a time and concentration 
dependent manner (9, 13, 20, 24, 32). The increase in cell death by VSV upon pretreatment 
with curcumin may be attributed to the reduction in crosstalk between proliferative pathways 
and an increase in apoptotic signaling. Future work in our lab will determine whether the 
activity of the transcription factor NF-κB, which controls the transcription of cytokines 
responsible for the production of antiviral factors, and Akt, a proliferative signal upregulated 
in many cancer cell lines, are altered upon combination treatments with flavokavain B and 
VSV .  
Similar to curcumin, studies have shown flavokavain B also exerts inhibitory effects 
on the activity of NF-κB. NF-κB regulates genes responsible for prosurvival factors and 
apoptotic resistance, like Bax and the inhibitory BCL protein family in addition to the type I 
IFNs necessary for inducing antiviral responses. Type 1 IFNs stimulate the production of the 
antiviral factors by the induction of the JAK/STAT cell signaling pathway. By interacting 
with their receptors on cells, IFNs activate the STAT complexes. Jaks are recruited to the 
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receptor and phosphorylate the STATs (STAT1 and STAT2) resulting in the formation of the 
IFN-stimulated gene factor 3 (ISGF3) complex. This complex contains a STAT1-STAT2 
heterodimer and interferon regulatory factor 9 (IRF9) that, when phosphorylated, translocates 
into the nucleus as a transcription factor that binds to the interferon stimulated response 
element (ISRE) promoter region. The STAT transcription factors regulate genes in the IFN-
stimulated response element (ISRE) that produce mRNAs expressing antiviral response 
factors. Antiviral factors include MX proteins, which reduce viral mRNA synthesis, ISG 
proteins, which shut off global protein expression, and cytoplasmic viral sensory molecule 
like RIG-I (23). Constitutive activation of NF-κB correlates to an increased antiviral 
response. An attractive treatment strategy in downregulating NF-κB is the use of modulatory 
plant compounds like curcumin.  
In addition to its effects on the antiviral response, NF-κB is also responsible for the 
production of survival responses like the upregulation of antiapoptotic factors and the 
production of inflammatory cytokines (i.e. interleukins and type 1 IFNs), and mediates 
crosstalk with proliferative pathways. For example, NF-κB mediates crosstalk with the Akt 
pathway through cyclooxygenase-2 (COX-2) (13, 24). In normal physiological responses, 
upstream signals cause IKK (IκB kinase) to phoslphorylate IκB, the inhibitory factor of the 
inactive NF-κB complex, which targets IκB for proteolytic degradation allowing the p50 and 
p65 subunits of NF-κB to translocate to the nucleus and begin its transcriptional activity. In 
some cancers NF-κB is constitutively active thus upregulating proliferative responses 
mediated by MAPK and Akt, anti-apoptotic factors, proinflammatory cytokines and antiviral 
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factors (24). NF-κB is only one facet of proliferative signaling pathways, though. Others, like 
the Akt pathway, are vital to normal and pathological proliferative signaling processes; 
therefore, it is possible that the synergistic effects of curcumin and virus on PC-3 cells may 
be mediated by multiple pathways.  
Studies have implicated the Akt signaling pathway is in the proliferative, survival, 
and the invasive nature of PC-3 cells. Therefore, the suppression of this pathway by 
curcumin may be contributing to the ability of VSV to promote killing of PC-3 cells. Akt 
controls the transcription of mRNAs responsible for resistance to apoptotic signaling and the 
progression of the cell cycle. Both flavokavain B and curcumin have previously been shown 
to downregulate Akt activation in cancer cells. Specifically, Hseu et al. (16) demonstrated 
that flavokavain B reduces BCL-2 and Bax expression in oral carcinoma cells HSC-3 by 
reducing Akt and MAPK signaling in addition to increasing reactive oxygen species (ROS), 
which induces mitochondrial outer membrane permeabilization (MOMP) and apoptosis in 
treated cells (16). Similarly, Gunadharini et al. (12) demonstrated that the total extract of 
neem leaves induced apoptosis in LNCaP and PC-3 cells and reduced Akt signaling. They 
demonstrated that this plant extract reduced BCL-2 mRNAs in treated cells and increased the 
expression of the pro-apoptotic factor Bad while decreasing Akt phosphorylation (12). The 
reduction of Akt activation by other naturally derived plant compounds has been shown to 
induce apoptosis and inhibit cell cycle progression in cancer cells suggesting a potential 
pathway by which curcumin and VSV may be synergistically acting. 
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Normally, the secretion of growth factors stimulates Akt activity. When these growth 
factors bind to receptors on the plasma membrane Ras and SOS are phosphorylated, initiating 
a signal cascade that ultimately leads to the upregulation of additional growth factor 
receptors in addition to anti-apoptotic proteins. Overstimulation or constitutive expression of 
growth factor receptors can lead to oncogenesis (35). An important mediator of this process 
is PTEN, a tumor suppressor that inhibits the phosphorylation of Ras by the growth receptor. 
Specifically, Mahimainathan and Choudry (25) showed that PTEN inactivates Platlet-derived 
Growth Factor (PDGF) and elucidated an unobserved mechanism not demonstrated in PTEN 
previously. PTEN was previously shown to inhibit PIP2 kinase activity, thereby resulting in a 
decrease of PIP3 and subsequently Akt activity (25). Akt is responsible for expressing 
proliferative and antiapoptotic factors; thus overexpression results in greater proliferative 
signaling and an increased resistance to apoptotic signals. In a study by Shulka et al. (34), 
prostate carcinomas differentially expressed lower levels of PTEN and higher phosphorylated 
Akt expression, particularly in LNCaP and PC-3 cells (34). By increasing Akt proliferative 
responses and decreasing PTEN tumor suppressor activity, prostate carcinomas like the PC-3 
cells used in this study more robustly express proliferative and apoptotic factors. By 
attenuating these responses in PC-3 cells through the use of phytochemicals like curcumin 
and flavokavain B, these cells may be rendered more susceptible to apoptotic signals from 
therapeutics or an oncolytic vector like VSV. 
In a review by Steelman et al., mutations in the Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR pathways are implicated in the apoptotic resistance and increased 
41 
 
 
proliferative signal exhibited by a multiplicity of cancer cell lines (35). The hyperactivation 
of these pathways results in crosstalk with other inflammatory pathways, like the NF-κB 
pathway and JAK/STAT pathway, which induces the transcription of antiapoptotic factors 
like the BCL-2 family, the overactivation of which increases BCL-2 antiapoptotic proteins in 
the cell. An upregulation in growth receptors upstream of the Akt pathway and mutations 
within the signal transduction molecules and inhibitory factors are required to overactivate 
Akt and increase proliferative signaling, specifically through MAPK activation. Additionally, 
mutations occur more frequently in upstream activators of Akt like Ras, Raf, and ERK, and 
rarely are associated with Akt mutations in human cancers. Hyperactivation of Akt usually 
results from overactivation of upstream regulators and the inhibition of tumor suppressor 
inhibitors like PTEN and p53 leading to a loss of sensitivity to apopotic signals. In some 
instances, weak mRNA expression regulated by Akt and ERK is overactive, leading to an 
increase in apoptotic resistance as well (35). 
The activation of Akt has been shown to promote the invasiveness of PC-3 and 
DU145 prostate cancer carcinomas. Shulka et al. (34) demonstrated that PC-3 and DU-145 
cells treated with PI3K and PTEN inhibitors, both of which are upstream activators of Akt, 
decreased the expression of matrix metalloproteinase (MMP)-9 and urokinase-type 
plasminogen activator (uPA) which are established markers for cellular invasion. They also 
show that these inhibitors decreased Akt phosphorylation but did not appreciably affect the 
total levels of endogenous Akt (34). These results suggest that Akt plays an important role 
not only in cell survival and proliferative responses, but also are important in the progression 
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of prostate cancer metastasis. Targeting Akt using natural therapeutics may render PC-3 cells 
more susceptible to apoptotic signals from VSV infection and reducing proliferative 
responses in these cells. 
Several studies have detailed some of the cell signaling pathways affected in cancer 
cells by curcumin, which may partially be responsible for the synergistic action of curcumin 
and VSV in Figure 1. Curcumin has been reported to inhibit proliferative pathways either 
directly or indirectly.  Curcumin has been shown to reduce pro-inflammatory factors like IL-
1, IL-6, TNFα, and COX-2, which are controlled by the NF-κB transcription factor (13, 24). 
COX-2 mediates crosstalk between the NF-κB pathway and the Akt and MAPK cell 
proliferative pathways. Furthermore, curcumin has been shown to reduce Akt and mTOR 
activation leading to the inhibition of downstream factors like PI3K and PDK1 (7, 9, 18). 
Curcumin not only serves to inhibit proliferative pathways through attenuation of NF-κB 
activity, but also by directly inhibiting activation of Akt, mTOR and MAPKs.  These 
pathways control proliferative responses upon induction by upstream signaling events, such 
as the binding of a mitogen to a growth receptor. Aberrant expression during oncogenesis 
decouples these responses from the appropriate receptors leading to overactivation of 
proliferative signaling in the absence of external signals.  
Previous studies have shown that curcumin upregulates TRAIL receptors in LNCaP 
prostate cancer cells and promotes apoptosis by upregulating the pro-apoptotic factors Bax 
and Bak and by reducing expression of the anti-apoptotic factor, BCL-2, in treated LNCaP 
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and PC-3 cells (32). My results did not show alterations in several pro- and anti-apoptotic 
factors upon treatment with curcumin. There was only a measurable decrease in BCL-XL 
expression in PC-3 cells upon infection with VSV. We are unsure why our results differ from 
previous studies and are currently investigating the possibility that other apoptotic pathways 
may be involved.  
Similar to curcumin, carnosic acid, another natural product that chemosensitizes 
cancer cells, reduces p50 and p65 NF-κB subunit translocation into the nucleus of treated 
PC-3 cells and promotes apoptosis by the intrinsic pathway by increasing the proapoptotic 
factor Bax and reducing the expression of the antiapoptotic factor BCL-2. In addition, 
carnosic acid promotes chemosensitation through the extrinsic pathways that caspase 8 and 9 
inhibitors are unable to reverse (18). This study suggests that natural compounds can 
modulate several apoptotic and proliferative pathways thereby rendering cancer cells more 
sensitive to killing. By reducing the crosstalk between different survival pathways, curcumin 
may be sensitizing PC-3 cells to VSV oncolytic activity; however, the exact pathways and 
mechanisms have yet to be revealed.  
In contrast to curcumin, data presented in Figures 3 and 4 suggest that flavokavain B 
does not augment the ability of VSV to kill PC-3 cells compared to virus infection alone. 
This may be due to the differences in which flavokavain B affects signaling pathways in 
cancer cells as compared to curcumin. Studies sugggest that flavokavain B modulates NF-κB 
and other pathways similarly to curcumin except the interacting proliferative pathways it 
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attenuates are slightly different.  Flavokavain B upregulates the proapoptotic factor Bax 
alone and does not attenuate COX-2, a mediator for crosstalk between Akt and NF-κB 
proliferative signaling (42). Both compounds reduce IKK activity which reduces NF-κB and 
MAPK activity (24). Flavokavain B exerts similar effects on NF-κB transcriptional activity 
in that flavokavain B inhibits IKK activity, thus leaving NF-κB bound to its inhibitor factor 
IKB in the cytoplasm. Flavokavain B differs from curcumin in that it preferentially regulates 
the death receptor apoptotic pathway as compared to the mitochondrial apoptotic pathway 
(41). Flavokavain B has been shown to increase caspase-8 activity and promote caspase-3 
cleavage which results in DNA fragmentation and apoptosis (16). Caspase-8 is activated 
upon the binding of a ligand, such as Fas, to a death receptor, which, in turn, activates the Fas 
associated death domain (FADD). In contrast, the intrinsic apoptotic pathway is activated 
once the ratio of proapoptotic factors, like Bax and Bad, to antiapoptotic factors, like BCL-
XL and BCL-2, increases, resulting in the leakage of cytochrome c from mitochondria 
initiating caspase-9 and caspase-3 cleavage; however, there can be crosstalk between these 
pathways mediated by caspase-8, which can also initiate caspase-3 cleavage (16). The 
potential synergistic action of curcumin and VSV infection may be attributed to how each 
strain induces apoptosis. 
 The wt and r-M51R-M mutant strains of VSV have previously been shown by Gaddy 
and Lyles (2004) to induce apoptosis through distinct pathways. The rM51R-M virus induces 
apoptosis through the cleavage of caspase-9 and the death receptor pathway and the wt 
induces caspase-8 activation and mitochondrial outer membrane permeabilization (10).  The 
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wt virus directly induces apoptosis in infected cells by the inhibition of host protein synthesis 
resulting in a reduction of mRNAs encoding antiapoptotic factors like BCL-2 and BCL-XL, 
which degrade quickly in the cytoplasm. The M protein mutant, rM51R-M, lacks the ability 
to shut off effectively host gene expression and relies on other viral components to induce 
apoptosis via the activation of caspase-8, caspase-9, and caspase-12, all of which are 
upstream activators of caspase-3 (10). These results indicate that the induction of apoptosis in 
M protein mutant VSV infected cells is dependent on crosstalk between the death receptor 
and mitochondrial pathways by caspase-8 activation. The data shown in Figure 1 indicates 
that curcumin potentiates VSV induced oncolysis more than flavokavain B perhaps by 
altering different pathways that increase cell death. The data presented in Figures 1-4 suggest 
that curcumin may downregulate pathways that render PC-3 cells sensitive to VSV induced 
oncolysis more effectively than flavokavain B. The exact nature of this synergistic action 
remains to be elucidated. 
The dysregulation of apoptotic factors has been shown in increase the 
chemoresistance of several cancer cell lines, including the PC-3 prostate carcinomas (9). Of 
these factors, the proapoptotic factor Bax and its ratio to the antiapoptotic factors BCL-2 and 
BCL-XL have been promising targets in sensitizing cancer cells to apoptotic signaling and 
subsequent death (32). In particular, the macronutrients Vitamin E and selenium were shown 
to increase the Bax/BCL-2 ratio in PC-3 and DU145 cells inducing apoptosis (31). Data 
shown in Figure 5 indicate that in PC-3 cells treated with curcumin and flavokavian B and 
infected with wt and m protein mutant VSV do not show significant differential expression of 
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the BCL-2 antiapoptotic; however, as mentioned before, there was a slight decrease in BCL-
XL in cells treated with curcumin and infected by both wt and M protein mutant virus (Fig. 
5A). This trend was not statistically significant given the number of replicates; however, it 
does implicate the involvement of the Bax regulated intrinsic apoptotic pathway. Given the 
significant reduction of cell viability in treated and infected cells shown in Fig. 1, it is 
plausible that other apoptotic signals may be involved in this process. Other mechanisms of 
apoptosis may be altered with pretreatment with curcumin. A study by Hilchie et al. (2010) 
showed that curcumin can affect lipid signaling pathways to induce apoptosis. Ceramide, an 
intracellular signaling lipid, accumulated in the mitochondrial outer membrane in PC-3 cells 
causing a subsequent release of cytochrome C and DNA fragmentation leading to cell death 
(14). The increase in cell killing in Figure 1 may be due to the induction of apoptosis 
involving one or more pathways acting in concert with the Bax regulated intrinsic apoptotic 
pathway.  
One potential drawback of attempting to use phytochemicals in conjunction with 
oncolytic viruses is the potential of inhibitory effects on viral replication processes. In 
particular, curcumin has been shown to inhibit hepatitis C virus (HCV) by activating 
proflierative pathways like heme oxygenase-1, Akt, and NF-κB (7). Crude leaf extracts of 
Curcumin longa, Cratoxylum formosum, Momordica charantia, and Moringa oleifera have 
also been shown to inhibit hepatitis B virus (HBV) replication in human hepatocellular 
carcinoma cells and reduce HBV induced cell killing (40). Here I show that both curcumin 
and flavokavain B do not reduce VSV protein expression (Figs 6, 7, and 8). Specifically, 
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neither curcumin nor flavokavain B significantly reduced the synthesis of VSVM or N 
proteins (Figs 6 and 7), both of which are required for budding and the release of viral 
progeny. Additionally, these compounds did not reduce viral gene expression as determined 
by the fluorescence of GFP engineered in the genomes of wt and M protein mutant VSV 
(Fig. 8). Curcumin has previously been shown to inhibit herpes simplex virus replication by 
blocking the expression of immediate-early genes soon after infection (21). Curcumin does 
not inhibit VSV gene expression 6h or 12h postinfection compared to virus alone (Fig. 8). 
Thus curcumin does not impede the expression of viral proteins in infected cells. This effect 
makes it an attractive candidate complementary therapeutic agent in VSV induced oncolytic 
activity. Similarly, flavokavain B does not inhibit VSV gene expression (Fig. 8) thereby 
increasing its potential as a complementary agent for potential oncolytic viral vectors.  
Vesicular Stomatitis Virus is currently being investigated as a potential oncolytic 
agent for use in cancer therapeutics. I used two strains, rwt and rM51R-M, to reduce cell 
viability in infected PC-3 prostate carcinomas. What makes the rM51R-M virus strain an 
attractive candidate for oncolytic virotherapy is the fact that this M protein mutant is 
replication competent, enabling it to spread to surrounding susceptible tissue including 
cancer metastases, while being avirulent. As compared to the wt strain of VSV (rwt virus), 
rM51R-M is effective, but safe in vivo (2, 3, 37, 38). In addition to VSV, other oncolytic 
viruses, such as recombinant adenoviruses, are also being developed for the treatment of 
cancers (1, 33). One advantage to using adenoviruses is the ubiquity of the adenovirus 
receptor on human cells, allowing a greater range of potential oncolytic targets. These 
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viruses, like VSV, can effectively kill cancer cells and are currently in clinical trials (1, 33). 
One potential drawback in the efficacy of oncolytic virotherapy is the fact that some cancers 
are resistant to infection due to the differential expression of proliferative and antiviral 
factors. Combination therapeutic approaches, such as the use of natural plant compounds to 
downregulate these pathways, are currently being investigated to determine if these 
compounds can augment an oncolytic viruses’ ability to kill cancer cells.  
My results indicated that 6h pretreatment of PC3 cells with curcumin increased VSV 
induced oncolysis at 24h postinfection (Fig. 1A). This increase in cell death was not due to 
the Bax mediated intrinsic apoptotic pathway (Fig. 5) suggesting apoptosis is being induced 
by another mediator of cell death. Lastly, both curcumin and flavokavian B do not decrease 
expression of viral genes in treated cells (Figs 5, 6 and 7), suggesting that they may be 
attractive candidates for other oncolytic vectors. In particular, curcumin potentiates the 
oncolytic activity of the rM51R-M virus, which is the strain being investigated as a potential 
oncolytic vector. Curcumin synergizes effectively with VSV by increasing VSV induced 
oncolysis and not inhibiting viral protein synthesis. This is the first study to determine if 
natural compounds promote VSV induced cancer cell killing. Future studies will determine 
the mechanisms by which these compounds promote VSV-induced oncolysis. Specifically, 
studies will determine if these compounds affect the Akt proliferative pathway and if they 
modulate NF-κB activation in VSV infected cells. Whether the downregulation of NF-κB is 
responsible for the increased oncolytic activity of VSV in cells treated with curcumin still 
needs to be investigated. Future work in our laboratory will determine if flavokavian B or 
49 
 
 
curcumin reduces NF-κB activation in infected cells as well as determine the relative gene 
expression of IFN stimulated genes by quantitative RT-PCR and microarray analysis. 
Additionally, the exact apoptotic mechanism by which VSV and curcumin potentiate cell 
death needs to be determined. The results from these studies will provide a platform for 
testing of additional natural compounds with the potential to augment VSV oncolytic 
therapies.  
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LIST OF ABBREVIATIONS 
7-AAD- 7-Aminoactinomycin D 
Akt- Protein Kinase B 
BCA- Bicinchoninic Acid Assay 
BHK- Baby Hamster Kidney cells 
BSA- Bovine Serum Albumin 
COX-2 cyclooxygenase-2 
CREB- cAMP Response Element Binding Protein 
ERK- Extra-cellular Related Kinase 
FADD- Fas Associated Death Domain 
Fas- Tumor Necrosis Factor- Alpha Receptor Member 6 
FBS- Fetal Bovine Serum 
GFP- Green Fluorescence Protein 
HBV- Hepatitis B Virus 
HCV- Hepatitis C Virus 
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HRP- Horseradish Peroxidase 
IFN- Interferon 
IκB- Inhibitors of κB 
IKK- Inhibitor of κB kinase 
IRF-9- Interferon Regulatory Factor 9 
ISGF3- Interferon-stimulated gene factor 3 
ISRE- Interferon Stimulated Response Element 
Jak- Janus Kinase 
LNCaP- LN Prostate Carcinoma 
M- Matrix Protein 
MAPK- Mitogen Activated Protein Kinase 
MMP-9- matrix metalloproteinase-9 
MOI- Multiplicity of Infection 
mRNA- Messenger Ribonucleic Acid 
mTOR- Mammalian Target of Rapamycin 
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MTT- (3-(4,5-Dimethlythiazol-2-yl)-2,5-diphenyltetralozium bromide 
N-Nucleocapsid Protein 
NF-κB- Nuclear Factor Kappa B 
OD- Optical Density 
p50- protein 50 
p53- Protein 53 
p65- protein 65 
PAGE- Polyacrylamide Gel Electrophoresis 
PBS- Phosphate Buffered Saline 
PC-3- Prostate Carcinoma Line 3 
PDGF- Platlet Derive Growth Factor 
PI3K- Phophoinositide 3-kinase 
PIP2- Phosphatidylinositol 4,5-bisphosphate 
PIP3- Phosphotidylinositol 3,4,5-triphosphate 
PKR- Protein Kinase R 
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PTEN-Phosphatase and Tensin Homolog 
Ras- Rat Sarcoma 
RIPA- Modified Radioimmunoprecipitation Buffer 
r-M51R-M- Recombinant Methionine to Arginine Substitution on Matrix Protein 
RPMI-Roswell Park Memorial Institute Medium 
rwt- Recombinant Wild Type 
SDS- Sodium Dodecyl-Sulfate 
SDS-PAGE- Sodium Dodecyl-Sulfate Polyacrylamide Gel Electrophoresis 
SOS- Son of Sevenless 
STAT- Signal Transducer and Activator of Transcription 
TBS- Tris Buffered Saline 
TBS-T- Tris-Buffered Saline- Tween 20 
TNF-α- Tumor Necrosis Factor- Alpha 
uPA- urokinase-type plasminogen activator 
VSV- Vesicular Stomatitis Virus 
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